Subject of the invention relates to compositions and methods for sterile, storage stable low dose atropine formulations with improved stability. Most preferably, the compositions presented herein are substantially free of preservatives and exhibit less than 0.35% tropic acid from the degradation of atropine. Advantageously, the formulations contemplated are also substantially free of preservatives.
展开▼